Source: International Journal of Gynecological Cancer. Unidade: FCF
ABNT
SARDINHA, Thais Gimenes et al. Diagnostic performance and clinical utility of p16 immunostaining in a population-based HPV DNA screening program. International Journal of Gynecological Cancer, v. 36, n. 2, p. 1-7, 2026Tradução . . Disponível em: https://dx.doi.org/10.1016/j.ijgc.2025.104451. Acesso em: 25 fev. 2026.APA
Sardinha, T. G., Vale, D. B., Discacciati, M. G., Triglia, R. de M., Rego, R. M., Jundurian, M., et al. (2026). Diagnostic performance and clinical utility of p16 immunostaining in a population-based HPV DNA screening program. International Journal of Gynecological Cancer, 36( 2), 1-7. doi:10.1016/j.ijgc.2025.104451NLM
Sardinha TG, Vale DB, Discacciati MG, Triglia R de M, Rego RM, Jundurian M, Campos CS, Zeferino LC, Teixeira JC. Diagnostic performance and clinical utility of p16 immunostaining in a population-based HPV DNA screening program [Internet]. International Journal of Gynecological Cancer. 2026 ; 36( 2): 1-7.[citado 2026 fev. 25 ] Available from: https://dx.doi.org/10.1016/j.ijgc.2025.104451Vancouver
Sardinha TG, Vale DB, Discacciati MG, Triglia R de M, Rego RM, Jundurian M, Campos CS, Zeferino LC, Teixeira JC. Diagnostic performance and clinical utility of p16 immunostaining in a population-based HPV DNA screening program [Internet]. International Journal of Gynecological Cancer. 2026 ; 36( 2): 1-7.[citado 2026 fev. 25 ] Available from: https://dx.doi.org/10.1016/j.ijgc.2025.104451
